8,532 reports of this reaction
1.5% of all CERTOLIZUMAB PEGOL reports
#15 most reported adverse reaction
SWELLING is the #15 most commonly reported adverse reaction for CERTOLIZUMAB PEGOL, manufactured by UCB, Inc.. There are 8,532 FDA adverse event reports linking CERTOLIZUMAB PEGOL to SWELLING. This represents approximately 1.5% of all 552,144 adverse event reports for this drug.
Patients taking CERTOLIZUMAB PEGOL who experience swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SWELLING is a less commonly reported adverse event for CERTOLIZUMAB PEGOL, but still significant enough to appear in the safety profile.
In addition to swelling, the following adverse reactions have been reported for CERTOLIZUMAB PEGOL:
The following drugs have also been linked to swelling in FDA adverse event reports:
SWELLING has been reported as an adverse event in 8,532 FDA reports for CERTOLIZUMAB PEGOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
SWELLING accounts for approximately 1.5% of all adverse event reports for CERTOLIZUMAB PEGOL, making it a notable side effect.
If you experience swelling while taking CERTOLIZUMAB PEGOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.